Single-session treatment for anxiety, depression, and stress
Development and Clinical Trial of a Transdiagnostic Single-session Treatment for Primary Care Patients
This study tests a one-time, 4-hour treatment to see if it can help primary care patients feel better by reducing anxiety, depression, and stress.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Luleå Tekniska Universitet Academic / other |
| Locations | 1 site (Luleå, Norrbotten) |
| Trial ID | NCT05784259 on ClinicalTrials.gov |
What this trial studies
This clinical trial tests a single-session, 4-hour transdiagnostic treatment program aimed at primary care patients experiencing anxiety, depression, or stress-related issues. The treatment incorporates techniques such as interoceptive exposure, behavioral activation, mindfulness, defusion, and psycho-education about emotions. The study evaluates the program's effectiveness in reducing symptoms and risk factors associated with these conditions, with follow-up assessments at 3 weeks and 6 months post-treatment.
Who should consider this trial
Good fit: Ideal candidates are primary care patients with mild to moderate symptoms of anxiety, mood disorders, or stress.
Not a fit: Patients currently undergoing psychotherapy or those with severe psychological disorders or high suicide risk may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could provide a quick and effective intervention for patients suffering from anxiety, depression, and stress.
How similar studies have performed: Other studies have shown promise with transdiagnostic approaches, but this specific single-session treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet the criteria for anxiety, mood disorder, or stress diagnosis * Symptoms are mild to moderate in severity Exclusion Criteria: * Already in ongoing psychotherapy * Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose * Has a comorbid personality disorder * Has a risk of suicide deemed other than low * Has other severe psychological disorders outside the scope of primary care * Is in a severely stressful social situation deemed incompatible with psychotherapy
Where this trial is running
Luleå, Norrbotten
- Region Norrbotten, Primary care — Luleå, Norrbotten, Sweden (Recruiting)
Study contacts
- Principal investigator: John Näsling, Master — Luleå tekniska universitet/Region Norrbotten
- Study coordinator: John Näsling, Master
- Email: john.nasling@ltu.se
- Phone: +4673 080 77 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.